Do aromatase inhibitors and tamoxifen affect oocyte numbers retrieved in oocyte or embryo banking cycles?
- 4 November 2024
- journal article
- research article
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 51 (2) , 104699
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Effects of using letrozole in combination with the GnRH antagonist protocol for patients with poor ovarian response: A meta-analysisJournal of Gynecology Obstetrics and Human Reproduction, 2021
- Effects of letrozole or tamoxifen coadministered with a standard stimulation protocol on fertility preservation among breast cancer patientsJournal of Assisted Reproduction and Genetics, 2021
- Estrogen signaling: An emanating therapeutic target for breast cancer treatmentEuropean Journal of Medicinal Chemistry, 2019
- Clomiphene citrate and letrozole to reduce follicle‐stimulating hormone consumption during ovarian stimulation: systematic review and meta‐analysisUltrasound in Obstetrics & Gynecology, 2017
- Comparison of ovarian stimulation response in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins to patients undergoing ovarian stimulation with gonadotropins alone for elective cryopreservation of oocytes†Gynecological Endocrinology, 2016
- Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trialsThe Lancet, 2015
- Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategiesFertility and Sterility, 2014
- The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: A pilot studyFertility and Sterility, 2005
- Effects of letrozole on superovulation with gonadotropins in women undergoing intrauterine inseminationFertility and Sterility, 2003
- Aromatase Inhibitors in Breast CancerNew England Journal of Medicine, 2003